We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Gf3.0

Growth Factors (topical) Research

Mostly mechanism / observationalModerate safety

6 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Growth Factors (topical) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from mixed-quality randomised trials published 2008–2023 with a typical study size of 50 participants.

Based on 6 studies · 2 RCTs · 142 total participants

Confidence

Low

By outcome

Skin healthModest, largely subjective reduction in fine lines/wrinkles in small/open-label trials (cosmetic, not a health outcome) · 12-24 weeks · Possible firmness/texture benefit via fibroblast/collagen stimulation; evidence weak and penetration-limited (cosmetic) · 12-24 weeks
Mostly mechanism / observational5 studies
Wound & ulcer healing
Too few graded studies1 study

Steady research

1 study in the last 5 years

200820152023

1Systematic Review2023

Three comparative RCTs showed no statistically significant differences between treatments. Studies were limited by heterogeneity.

Quinlan DJ, Ghanem AM, Hassan H. · J Cosmet Dermatol (2023)

Pooled 33 studies (9 RCTs, 24 uncontrolled series; 1180 participants, 23 preparations) — only nine used a control
Improvements were modest (texture median <50%, wrinkles <35%) and participant-rated benefit exceeded investigator-rated
Three comparative RCTs showed no significant difference between treatments — the key counter-evidence

View source

2RCTn=60 · small study2008

Treatment with the active gel for 3 months produced greater reduction in fine lines and wrinkles than the vehicle treatment as measured by objective and subjective assessment techniques.

Mehta RC, Smith SR, Grove GL, Ford RO, Canfield W, Donofrio LM, Flynn TC, Leyden JJ. · J Drugs Dermatol (2008)

Double-blind vehicle-controlled trial (n=60) of a gel with >110 growth factors/cytokines from human dermal fibroblasts, twice daily
Active gel reduced fine lines/wrinkles more than vehicle, with results significant or trending toward significance
Manufacturer-conducted (SkinMedica) — an industry-funding caveat

3Review2014

Data of evidence levels II and III support the use for skin rejuvenation of topical GFs derived from sources including secretions or lysate of human dermal fibroblasts, and secretions of the snail Cryptomphalus aspersa.

Fabi S, Sundaram H. · Facial Plast Surg (2014)

Review of the mechanism: growth factors/cytokines control cell proliferation/differentiation, with wound-healing pathways paralleling photoaging
Topical growth-factor support rests on lower-tier level II-III evidence (fibroblast secretions/lysate, snail secretions), not high-power RCTs
Explicitly notes the evidence gaps between experimental observations and proven clinical benefit

View source

4RCTn=50 · small study2020

Both groups showed significant improvements in fine lines and wrinkles. PGA and IGA assessments indicated greater improvement in the active treatment group.

Lim VZ, Yong AA, Tan WPM, Zhao X, Vitale M, Goh CL. · J Clin Aesthet Dermatol (2020)

Three-month double-blind vehicle-controlled trial (n=50) of snail-derived (growth-factor-like) secretion plus snail egg extract
Both active AND vehicle groups improved significantly in fine lines/wrinkles; active showed greater global-assessment improvement
Industry-funded; the vehicle improving wrinkles as much as active on the headline endpoint is the counter-evidence

5Open-Labeln=14 · very small study2008

Improved clinical appearance of periorbital and perioral wrinkles by 33% and 25% on average, respectively, was demonstrated.

Hussain M, Phelps R, Goldberg DJ. · J Cosmet Laser Ther (2008)

Open-label, uncontrolled study (n=14) of a growth-factor/cytokine cream twice daily for 6 months with pre/post biopsies
~33% periorbital and ~25% perioral wrinkle improvement, plus histologic increases in epidermal thickness and dermal fibroblast density
No control or vehicle arm and very small sample — improvement cannot be separated from moisturization/placebo

View source

6Pilotn=18 · very small study2015

The final average Merz grade was 1.63 (SEM = .273), statistically significantly lower than the mean baseline average of 2.06 (SEM = .232) (P = .0019).

Seidel R, Moy RL. · J Drugs Dermatol (2015)

Single-arm pilot (n=18) of a topical EGF serum to the infraorbital area twice daily for 12 weeks
Merz Infraorbital Hollowness and IGA scores improved significantly from baseline, but with no control or vehicle comparison
Representative of the small, open-label EGF pilots that dominate this category

View in Research Library

Growth Factors (topical) Research

Mostly mechanism / observational

Topical growth factor preparations for facial skin rejuvenation: A systematic review.

Reduction in facial photodamage by a topical growth factor product.

The potential of topical and injectable growth factors and cytokines for skin rejuvenation.

Efficacy and Safety of a New Cosmeceutical Regimen Based on the Combination of Snail Secretion Filtrate and Snail Egg Extract to Improve Signs of Skin Aging.

Clinical, histologic, and ultrastructural changes after use of human growth factor and cytokine skin cream for the treatment of skin rejuvenation.

Reduced appearance of under-eye bags with twice-daily application of epidermal growth factor (EGF) serum: a pilot study.